Dyslipidemia and aortic valve disease

Area of Science:

• Cardiology
• Vascular Biology
• Preventive Medicine

Background:

• Degenerative aortic stenosis (AS) is a prevalent heart valve disease in adults.
• Understanding AS pathophysiology and risk factors, including lipid factors, is advancing.
• Low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] play significant roles.

Purpose of the Study:

• To review the interrelationship of dyslipidemia, particularly hypercholesterolemia and Lp(a), in the development and prognosis of valvular AS.
• To explore the potential of drug therapies targeting risk factors to delay AS progression.
• To highlight advancements in early detection and future therapeutic strategies.

Main Methods:

• Review of recent observational studies and Mendelian randomization studies.
• Analysis of data from studies like SAFEHEART focusing on lipid factors.
• Synthesis of current understanding of AS pathophysiology and risk factors.

Main Results:

• Hypercholesterolemia and Lp(a) are significant predictors of AS development and prognosis.
• The SAFEHEART study provided key insights into the roles of LDL-C and Lp(a).
• Emerging evidence suggests that managing lipid risk factors may influence AS progression.

Conclusions:

• Dyslipidemia, especially elevated LDL-C and Lp(a), is central to AS development and prognosis.
• New imaging tools offer potential for earlier AS detection.
• Future therapies targeting proprotein convertase subtilisin/kexin type 9 and Lp(a) may delay AS progression and reduce the need for aortic valve replacement.